Brief: Alphamab Oncology Granted Us Fda Orphan Drug Designation To Combination Therapy Of Kn026 And Kn046 Developed By Unit
23/12/2020 01:30
Dec 23 (Reuters) - Alphamab Oncology 9966.HK :
* ALPHAMAB ONCOLOGY - US FDA GRANTED ORPHAN DRUG DESIGNATION
TO
COMBINATION THERAPY OF KN026 AND KN046 DEVELOPED BY UNIT
Source text for Eikon: ID:nHKS71YgZG
Further company coverage: 9966.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alphamab Oncology
See all newsBrief: Alphamab Oncology Says Fei Wang Resigns As Chief Financial Officer
Brief: Alphamab Oncology Says First Patient Dosed In Phase III Clinical Study Of JSKN033 Monotherapy For Treatment Of Cervical Cancer
Brief: Alphamab Oncology Says Board Resolves To Repurchase Shares Up To HK$80 Million In Value
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab With HB1801 For Her2+ Advanced Breast Cancer
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab (KN026)